OTCMKTS:EVTCY Evotec (EVTCY) Stock Price, News & Analysis $2.78 +0.04 (+1.46%) As of 05/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsBuy This Stock About Evotec Stock (OTCMKTS:EVTCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evotec alerts:Sign Up Key Stats Today's Range$2.73▼$2.7850-Day Range$2.31▼$3.3052-Week Range$14.22▼$26.57Volume36,143 shsAverage Volume2,407 shsMarket Capitalization$918.01 millionP/E Ratio6.78Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evotec SE is a Germany-based biotechnology company specializing in drug discovery alliance and development partnerships. Headquartered in Hamburg, the company collaborates with pharmaceutical and biotechnology firms to deliver integrated solutions across the drug discovery and development continuum. Its offerings span from target identification and validation to lead optimization, preclinical development and manufacturing support. The company’s platform combines expertise in assay development, high-throughput screening, medicinal chemistry, in vivo pharmacology and safety assessment. Evotec operates multiple research sites across Europe, North America and Asia, leveraging proprietary technologies and a multidisciplinary team to advance programs in areas such as neuroscience, oncology, metabolic and infectious diseases. Founded in 1993 following the consolidation of various German research institutions, Evotec has grown through strategic acquisitions and collaborations. The company went public on the Frankfurt Stock Exchange in 1999 and established an American depositary receipt program under the ticker EVTCY to broaden its investor base. Under the leadership of Chief Executive Officer Werner Lanthaler, Evotec maintains a global footprint with key facilities in Germany, the United Kingdom, France, Switzerland and the United States. Its partnership model is built on long-term alliances, milestone-driven collaborations and risk-sharing arrangements aimed at accelerating the delivery of novel therapeutic candidates.AI Generated. May Contain Errors. Read More Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVTCY Stock News HeadlinesEvotec SE: Evotec Receives Grants to Advance Tuberculosis TreatmentApril 30, 2026 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related VirusesMarch 23, 2026 | finanznachrichten.deThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000. | Behind the Markets (Ad)Evotec SE: Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study InitiationMarch 19, 2026 | finanznachrichten.deEvotec SE: Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor RelationsJanuary 2, 2026 | finanznachrichten.deEvotec SE: Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation PartnershipNovember 12, 2025 | finanznachrichten.deEvotec SE: In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus RoyaltiesNovember 6, 2025 | finanznachrichten.deEvotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution | EVO Stock NewsAugust 13, 2025 | gurufocus.comSee More Headlines EVTCY Stock Analysis - Frequently Asked Questions How have EVTCY shares performed this year? Evotec's stock was trading at $3.08 at the beginning of the year. Since then, EVTCY shares have decreased by 9.7% and is now trading at $2.78. When did Evotec's stock split? Shares of Evotec split on the morning of Wednesday, October 20th 2021.The 3-1 split was announced on Wednesday, October 20th 2021. The newly minted shares were issued to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Evotec have any subsidiaries? Evotec subsidiaries include Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others. How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EVTCY CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees4,200Year Founded1993Profitability EPS (Trailing Twelve Months)$0.41 Trailing P/E Ratio6.78 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales1.60 Cash Flow$0.03 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book1.10Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$918.01 million OptionableNot Optionable Beta0.98 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:EVTCY) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
